173 related articles for article (PubMed ID: 10103184)
1. 9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA.
Van Rompay KK; Cherrington JM; Marthas ML; Lamy PD; Dailey PJ; Canfield DR; Tarara RP; Bischofberger N; Pedersen NC
Antimicrob Agents Chemother; 1999 Apr; 43(4):802-12. PubMed ID: 10103184
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA.
Van Rompay KK; Miller MD; Marthas ML; Margot NA; Dailey PJ; Canfield DR; Tarara RP; Cherrington JM; Aguirre NL; Bischofberger N; Pedersen NC
J Virol; 2000 Feb; 74(4):1767-74. PubMed ID: 10644348
[TBL] [Abstract][Full Text] [Related]
3. 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques.
Van Rompay KK; Cherrington JM; Marthas ML; Berardi CJ; Mulato AS; Spinner A; Tarara RP; Canfield DR; Telm S; Bischofberger N; Pedersen NC
Antimicrob Agents Chemother; 1996 Nov; 40(11):2586-91. PubMed ID: 8913470
[TBL] [Abstract][Full Text] [Related]
4. Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques.
Van Rompay KK; Marthas ML; Lifson JD; Berardi CJ; Vasquez GM; Agatep E; Dehqanzada ZA; Cundy KC; Bischofberger N; Pedersen NC
AIDS Res Hum Retroviruses; 1998 Jun; 14(9):761-73. PubMed ID: 9643376
[TBL] [Abstract][Full Text] [Related]
5. Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn Rhesus macaques.
van Rompay KK; Dailey PJ; Tarara RP; Canfield DR; Aguirre NL; Cherrington JM; Lamy PD; Bischofberger N; Pedersen NC; Marthas ML
J Virol; 1999 Apr; 73(4):2947-55. PubMed ID: 10074144
[TBL] [Abstract][Full Text] [Related]
6. Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection.
Van Rompay KK; Berardi CJ; Aguirre NL; Bischofberger N; Lietman PS; Pedersen NC; Marthas ML
AIDS; 1998 Jun; 12(9):F79-83. PubMed ID: 9662190
[TBL] [Abstract][Full Text] [Related]
7. Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.
Van Rompay KK; Johnson JA; Blackwood EJ; Singh RP; Lipscomb J; Matthews TB; Marthas ML; Pedersen NC; Bischofberger N; Heneine W; North TW
Retrovirology; 2007 Apr; 4():25. PubMed ID: 17417971
[TBL] [Abstract][Full Text] [Related]
8. Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques.
Metzner KJ; Binley JM; Gettie A; Marx P; Nixon DF; Connor RI
Retrovirology; 2006 Dec; 3():97. PubMed ID: 17184540
[TBL] [Abstract][Full Text] [Related]
9. Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine.
Murry JP; Higgins J; Matthews TB; Huang VY; Van Rompay KK; Pedersen NC; North TW
J Virol; 2003 Jan; 77(2):1120-30. PubMed ID: 12502828
[TBL] [Abstract][Full Text] [Related]
10. Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies.
Tarantal AF; Marthas ML; Shaw JP; Cundy K; Bischofberger N
J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Apr; 20(4):323-33. PubMed ID: 10096575
[TBL] [Abstract][Full Text] [Related]
11. Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques.
Van Rompay KK; Singh RP; Heneine W; Johnson JA; Montefiori DC; Bischofberger N; Marthas ML
J Virol; 2006 Jul; 80(13):6399-410. PubMed ID: 16775328
[TBL] [Abstract][Full Text] [Related]
12. Transient early post-inoculation anti-retroviral treatment facilitates controlled infection with sparing of CD4+ T cells in gut-associated lymphoid tissues in SIVmac239-infected rhesus macaques, but not resistance to rechallenge.
Lifson JD; Piatak M; Cline AN; Rossio JL; Purcell J; Pandrea I; Bischofberger N; Blanchard J; Veazey RS
J Med Primatol; 2003 Aug; 32(4-5):201-10. PubMed ID: 14498980
[TBL] [Abstract][Full Text] [Related]
13. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine.
Tsai CC; Follis KE; Sabo A; Beck TW; Grant RF; Bischofberger N; Benveniste RE; Black R
Science; 1995 Nov; 270(5239):1197-9. PubMed ID: 7502044
[TBL] [Abstract][Full Text] [Related]
14. Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal.
Van Rompay KK; Trott KA; Jayashankar K; Geng Y; LaBranche CC; Johnson JA; Landucci G; Lipscomb J; Tarara RP; Canfield DR; Heneine W; Forthal DN; Montefiori D; Abel K
Retrovirology; 2012 Jul; 9():57. PubMed ID: 22805180
[TBL] [Abstract][Full Text] [Related]
15. The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunologic parameters.
Van Rompay KK; Singh RP; Brignolo LL; Lawson JR; Schmidt KA; Pahar B; Canfield DR; Tarara RP; Sodora DL; Bischofberger N; Marthas ML
J Acquir Immune Defic Syndr; 2004 Aug; 36(4):900-14. PubMed ID: 15220696
[TBL] [Abstract][Full Text] [Related]
16. Effect of PMPA and PMEA on the kinetics of viral load in simian immunodeficiency virus-infected macaques.
Silvera P; Racz P; Racz K; Bischofberger N; Crabbs C; Yalley-Ogunro J; Greenhouse J; Jiang JB; Lewis MG
AIDS Res Hum Retroviruses; 2000 May; 16(8):791-800. PubMed ID: 10826485
[TBL] [Abstract][Full Text] [Related]
17. Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection.
Van Rompay KK; McChesney MB; Aguirre NL; Schmidt KA; Bischofberger N; Marthas ML
J Infect Dis; 2001 Aug; 184(4):429-38. PubMed ID: 11471100
[TBL] [Abstract][Full Text] [Related]
18. CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment.
Van Rompay KK; Singh RP; Pahar B; Sodora DL; Wingfield C; Lawson JR; Marthas ML; Bischofberger N
J Virol; 2004 May; 78(10):5324-37. PubMed ID: 15113912
[TBL] [Abstract][Full Text] [Related]
19. Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques.
Rosenwirth B; ten Haaft P; Bogers WM; Nieuwenhuis IG; Niphuis H; Kuhn EM; Bischofberger N; Heeney JL; Uberla K
J Virol; 2000 Feb; 74(4):1704-11. PubMed ID: 10644340
[TBL] [Abstract][Full Text] [Related]
20. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.
Cranage M; Sharpe S; Herrera C; Cope A; Dennis M; Berry N; Ham C; Heeney J; Rezk N; Kashuba A; Anton P; McGowan I; Shattock R
PLoS Med; 2008 Aug; 5(8):e157; discussion e157. PubMed ID: 18684007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
